logo-loader

Akari Therapeutics expects readouts from two key Phase II studies by year-end

Published: 08:04 11 Jul 2019 EDT

Clive Richardson, chief executive of Akari Therapeutics PLC (NASDAQ:AKTX), introduces the business to Proactive London and outlines some of the work they're doing in the area of acute and chronic inflammation.

Discussing their protein Nomacopan, he says it's currently being clinically evaluated in four indications including a severe blistering skin disease and a sight threatening surface of the eye condition.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 12 minutes ago